Viral Genetics, Inc. (VRAL: Pink Sheets) Viral Genetics, Inc. is a biotechnology company that discovers and develops immune-based therapies for HIV and AIDS using its thymus nuclear protein compound (TNP) and more recently experimentally and computationally derived targeted peptides. The … Continue reading →

Viral Genetics, Inc (VRAL: Pink Sheets) 21st Century Investor Relations, Inc, is an Investor Relations 2.0  firm that helps small and micro cap companies build investor audiences through the use of Internet marketing and Social Media (“Investor Relations 2.0” or … Continue reading →

We have a follow up piece of our initial April 12, 2010 profile report coming out in the next few days. VRAL trading at its support level is an ideal accumulation point for those looking to build a position in … Continue reading →

The news from Monday was probably the most significant piece of news in the 10 year plus history of Viral Genetics Inc. (VRAL: PINK SHEETS) http://finance.yahoo.com/news/Viral-Genetics-HIVAIDS-bw-1583274227.html?x=0&.v=1 The question is how much money would it cost to conduct research and possible … Continue reading →

Professor Shattock research team at St. George’s University of London received a £10.7 million ($15.3 million) grant from the Grand Challenge for Global Health Initiative, co-funded by the Welcome Trust and the Bill & Melinda Gates Foundation. Shattock’s team also … Continue reading →

Big News on VRAL this morning…. Viral Genetics HIV/AIDS Compound Researched by London Team: http://finance.yahoo.com/news/Viral-Genetics-HIVAIDS-bw-1583274227.html?x=0&.v=1 Disclaimer: Institutional Analyst Inc., is an Investor Relations firm specializing in Investment Research and Investment Research Distribution. We specialize in getting (or creating) coverage for … Continue reading →

Last week 34% break out move to $.067, failed to materialize after encountering resistance in the $.06 area….the good news is the stock has pulled back to the $.05 support level were it has popped multiple times in the past … Continue reading →

A message to all members of 21ST CENTURY INVESTOR RELATIONS From Our Friends at the Biotech Stock Review, Thursday, 6/03/2010 http://www.biotechstockreview.com 1. Viral Genetics (VRAL) Mid-Year Update. A lot to read here. Even more, in-between-the-lines, to read . There is … Continue reading →

Expanding research capability Dr. Newell Texas A&M obtains $1,000,000 in new funding Patented Metabolic Disruption technology has potential to destroy cancer cells with additional potential bio fuel applications http://finance.yahoo.com/news/Viral-Genetics-Appoints-Dr-bw-2882412619.html?x=0&.v=1 http://21webir.com/stocks-and-sectors/disclaimer-for-viral-genetics-vral-pink-sheets/

After yesterday’s 34% move which probably indicates normal profit taking and a shakeout of the stock out of weak hands (traders). We would like to see the following to get a 2nd bullish confirmation signal. 1) $.06 area maintained and … Continue reading →